Mineralys Therapeutics, Inc. Common Stock (MLYS NASDAQ) stock market data APIs
$43.1975
1.08(2.5%)
as of November 18, 2025
Try our APIs with
free plan!
Mineralys Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Prev. Close
43.1975
Open
44.282
High
44.3585
Low
42.1592
52 wk Range
8.241-47.65
Market Cap
3 503 M
Shares Outstanding
79 140 K
EPS
-0.52
Beta
0.399
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mineralys Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mineralys Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Mineralys Therapeutics, Inc. Common Stock Fundamental Data
Mineralys Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -184 030 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Mineralys Therapeutics, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.64
Get Mineralys Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mineralys Therapeutics, Inc. Common Stock News
New
Mineralys outlines NDA submission timeline and advances lorundrostat trials amid expanded clinical focus
Earnings Call Insights: Mineralys Therapeutics (MLYS) Q3 2025 MANAGEMENT VIEW * Jon Congleton, President and CEO, shared that Mineralys received pre-NDA feedback from the FDA with "no surprises" a...
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conferen...
After-Hours Earnings Report for November 10, 2025 : OXY, RKLB, ASTS, RGTI, SARO, WULF, BLTE, PLUG, MLYS, TDW, BBAI, JAMF
The following companies are expected to report earnings after hours on 11/10/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Occidental Petroleum Corporation (OXY)...
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GL...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
